| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1013940552 |
| P356 | DOI | 10.1046/J.1523-1755.2001.060003831.X |
| P3181 | OpenCitations bibliographic resource ID | 832747 |
| P698 | PubMed publication ID | 11532079 |
| P5875 | ResearchGate publication ID | 11814291 |
| P50 | author | Giuseppe Remuzzi | Q16561003 |
| Piero Ruggenenti | Q92877106 | ||
| P2093 | author name string | M Noris | |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | thrombocytopenia | Q585285 |
| thrombotic thrombocytopenic purpura | Q1426491 | ||
| P304 | page(s) | 831-46 | |
| P577 | publication date | 2001-09-01 | |
| P1433 | published in | Kidney International | Q6404823 |
| P1476 | title | Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura | |
| P478 | volume | 60 |
| Q33372537 | A 32-year-old patient with diarrhoea and acute kidney failure |
| Q59137614 | A Case of Typical Hemolytic Uremic Syndrome in an Adult |
| Q48201612 | A STARD-compliant prediction model for diagnosing thrombotic microangiopathies |
| Q33361427 | A case study of thrombotic thrombocytopaenic purpura: a 'powerful poison'. |
| Q33425651 | ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment |
| Q34922868 | Action of shiga toxin type-2 and subtilase cytotoxin on human microvascular endothelial cells |
| Q33413460 | Acute Progression of Adult-Onset Atypical Hemolytic-Uremic Syndrome due to CFH Mutation: A Case Report. |
| Q33419414 | Acute renal failure is prevalent in patients with thrombotic thrombocytopenic purpura associated with low plasma ADAMTS13 activity |
| Q33364401 | Administration of ricin induces a severe inflammatory response via nonredundant stimulation of ERK, JNK, and P38 MAPK and provides a mouse model of hemolytic uremic syndrome |
| Q33376471 | Adult hemolytic-uremic syndrome associated with urosepsis due to Shigatoxin-producing Escherichia coli O138:H-. |
| Q49789113 | Advances in our Understanding of the Pathogenesis of Hemolytic Uremic Syndromes. |
| Q33392316 | Advances in our understanding of the pathogenesis of glomerular thrombotic microangiopathy |
| Q35574005 | An unusual cause of acute renal failure in sickle cell disease |
| Q98290680 | Atypical Hemolytic Uremic Syndrome Associated With Clostridium Difficile Infection |
| Q39112532 | Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management |
| Q26864297 | Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature |
| Q54207419 | Atypical hemolytic uremic syndrome and eculizumab therapy in children. |
| Q35026701 | Atypical hemolytic uremic syndrome and mutation analysis of factor H gene in two Tunisian families |
| Q33400211 | Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics |
| Q33441892 | Atypical hemolytic uremic syndrome with MCP mutations preceded by respiratory infection |
| Q54183133 | Atypical hemolytic uremic syndrome: Korean pediatric series. |
| Q42108749 | Atypical hemolytic-uremic syndrome (HUS) with recovery after a long-lasting anuria: a case report |
| Q33395953 | Atypical hemolytic-uremic syndrome in a child presenting with malignant hypertension |
| Q38596477 | Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site |
| Q88101871 | Brain microvascular endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells |
| Q40292881 | C3b and factor H: key components of the complement system |
| Q33423056 | Campylobacter-Associated Hemolytic Uremic Syndrome Associated with Pulmonary-Renal Syndrome |
| Q36510758 | Cardiovascular disease after Escherichia coli O157:H7 gastroenteritis |
| Q41244904 | Catastrophic antiphospholipid antibody syndrome in a child with thrombotic microangiopathy |
| Q81412262 | Catastrophic antiphospholipid syndrome in a 14-year-old child |
| Q57702450 | Chapter 14 Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura |
| Q33557728 | Chemokine expression in the monocytic cell line THP-1 in response to purified shiga toxin 1 and/or lipopolysaccharides |
| Q33433038 | Clinical features, therapeutic interventions and long-term aspects of hemolytic-uremic syndrome in Norwegian children: a nationwide retrospective study from 1999-2008. |
| Q33385986 | Clinical practice. Today's understanding of the haemolytic uraemic syndrome |
| Q42654051 | Collapsing glomerulopathy and hemolytic uremic syndrome associated with falciparum malaria: completely reversible acute kidney injury |
| Q89852321 | Combination of plasma exchange and haemofiltration for treating thrombotic microangiopathy in children |
| Q40133558 | Comparison of a Shiga Toxin Enzyme-Linked Immunosorbent Assay and Two Types of PCR for Detection of Shiga Toxin-Producing Escherichia coli in Human Stool Specimens |
| Q61798114 | Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome |
| Q33409285 | Complement activation associated with ADAMTS13 deficiency in human and murine thrombotic microangiopathy |
| Q33432063 | Complement and the kidney in the setting of Shiga-toxin hemolytic uremic syndrome, organ transplantation, and C3 glomerulonephritis |
| Q33357576 | Complement dysregulation in haemolytic uraemic syndrome |
| Q33359632 | Complement factor H deficiency in acute allograft glomerulopathy and post-transplant hemolytic uremic syndrome |
| Q33405522 | Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome |
| Q33374215 | Complete factor H deficiency-associated atypical hemolytic uremic syndrome in a neonate |
| Q33419244 | Consequences of hemolytic uremic syndrome among hemodialysis patients |
| Q33409030 | Current evidence for the role of complement in the pathogenesis of Shiga toxin haemolytic uraemic syndrome |
| Q33421382 | Cutaneous and renal glomerular vasculopathy as a cause of acute kidney injury in dogs in the UK. |
| Q64043944 | Description of the Use of Plasma Exchange in Dogs With Cutaneous and Renal Glomerular Vasculopathy |
| Q33378553 | Development of an experimental hemolytic uremic syndrome in rats |
| Q33908301 | Differing tales of two patients after receiving a kidney transplant from a donor with disseminated intravascular coagulation |
| Q33419716 | Does corticosteroid treatment cause prolonged recovery and increased total bilirubin level in severe ADAMTS-13-deficient TTP patient? |
| Q33413018 | Dose kidney transplant nephrectomy stop disease progression in plasma exchange resistant post transplant hemolytic uremic syndrome? A case report |
| Q57495722 | Drug-induced Thrombotic Microangiopathy Caused by Gemcitabine |
| Q40612027 | Early Terminal Complement Blockade and C6 Deficiency Are Protective in Enterohemorrhagic Escherichia coli-Infected Mice |
| Q45961802 | End-stage renal disease from glomerulonephritis associated with anti-phospholipid syndrome. |
| Q33401369 | Endothelial cells and thrombotic microangiopathy |
| Q33389014 | Endothelial von Willebrand factor release due to eNOS deficiency predisposes to thrombotic microangiopathy in mouse aging kidney |
| Q31010561 | Epidemiology of haemolytic uremic syndrome in children. Data from the North Italian HUS network. |
| Q33388583 | Etanercept-refractory adult-onset Still's disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab |
| Q38024274 | Facing glycosphingolipid-Shiga toxin interaction: dire straits for endothelial cells of the human vasculature |
| Q33357579 | Familial haemolytic uraemic syndrome and an MCP mutation |
| Q33400197 | Fulminant thrombotic microangiopathy in pediatrics: where diagnostic and therapeutic dilemmas meet |
| Q47100667 | Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life-saving treatment |
| Q33361258 | Gemcitabine-associated thrombotic microangiopathy |
| Q58551524 | Gemcitabine-induced haemolytic uremic syndrome, although infrequent, can it be prevented: A case report and review of literature |
| Q24685473 | Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome |
| Q34122035 | Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis |
| Q33344468 | HIV associated thrombotic microangiopathy |
| Q33441069 | HUS and atypical HUS. |
| Q30244707 | Haemolytic uraemic syndrome |
| Q33349831 | Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries |
| Q33429070 | Haemolytic uraemic syndrome with peripheral gangrene and Kawasaki disease in a 15-month-old child |
| Q33417237 | Hemoconcentration: a major risk factor for neurological involvement in hemolytic uremic syndrome |
| Q57701679 | Hemolytic uremic syndrome |
| Q33598544 | Hemolytic uremic syndrome after renal transplantation |
| Q33348759 | Hemolytic uremic syndrome associated with group A beta-hemolytic streptococcus |
| Q33416236 | Hemolytic uremic syndrome associated with paraquat intoxication |
| Q33372080 | Hemolytic uremic syndrome in an infant following Bordetella pertussis infection |
| Q33349440 | Hemolytic uremic syndrome: A case report from Africa |
| Q33365746 | Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation |
| Q33378856 | Hemolytic-uremic syndrome in a postpartum mare concurrent with encephalopathy in the neonatal foal |
| Q33381110 | High-dose immunoglobulin infusion for thrombotic thrombocytopenic purpura refractory to plasma exchange and steroid therapy |
| Q33398967 | Idiopathic combined, autoantibody-mediated ADAMTS-13/factor H deficiency in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in a 17-year-old woman: a case report |
| Q58617980 | Impact of a multidisciplinary team for the management of thrombotic microangiopathy |
| Q52913437 | Increased TRPC3 expression in vascular endothelium of patients with malignant hypertension. |
| Q44899011 | Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination |
| Q30310446 | Induction by sphingomyelinase of shiga toxin receptor and shiga toxin 2 sensitivity in human microvascular endothelial cells |
| Q43188164 | Inherited thrombotic thrombocytopenic purpura |
| Q24241470 | Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura |
| Q79290901 | Intravenous gamma globulin for thrombotic microangiopathy of unknown etiology |
| Q28188198 | Is ADAMTS-13 deficiency specific for thrombotic thrombocytopenic purpura? No |
| Q33374687 | Late mortality from thrombotic microangiopathy after liver transplantation: report of a case |
| Q33412732 | Life-threatening complications of adult-onset Still's disease |
| Q33386213 | Mac-1 (CD11b/CD18) links inflammation and thrombosis after glomerular injury |
| Q64039312 | Management of STEC Gastroenteritis: Is There a Role for Probiotics? |
| Q33396885 | Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study |
| Q36093532 | Microwave-accelerated bioassay technique for rapid and quantitative detection of biological and environmental samples. |
| Q33380705 | Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody |
| Q33405452 | Multifaceted hemolytic uremic syndrome in pediatrics |
| Q33384039 | Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome |
| Q33392948 | New insights into postrenal transplant hemolytic uremic syndrome. |
| Q37786659 | Non-O157 Shiga toxin-producing Escherichia coli in foods |
| Q33410111 | Novel use of intravenous immunoglobulin G in complement factor H missense mutation: a case report |
| Q44596912 | Outcome of Plasma Exchange Therapy in Thrombotic Microangiopathy After Renal Transplantation |
| Q38427670 | Parietal and intravascular innate mechanisms of vascular inflammation |
| Q33375692 | Pathogenesis and prognosis of thrombotic microangiopathy |
| Q33712512 | Pathogenesis of Escherichia coli O157:H7 strain 86-24 following oral infection of BALB/c mice with an intact commensal flora |
| Q33431806 | Pathology Consultation on the Diagnosis and Treatment of Thrombotic Microangiopathies (TMAs). |
| Q33406887 | Postoperative hemolytic uremic syndrome with renal cortical necrosis following laparoscopic hemicolectomy |
| Q24613907 | Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype |
| Q33403361 | Renal and neurological involvement in typical Shiga toxin-associated HUS. |
| Q58333251 | Renal involvement in human parvovirus B19 infection |
| Q35452456 | Renal involvement in idiopathic hypereosinophic syndrome |
| Q33382787 | Renal thrombotic microangiopathy after hematopoietic cell transplant: role of GVHD in pathogenesis |
| Q46865405 | Role of the renin angiotensin system in TNF-alpha and Shiga-toxin-induced tissue factor expression |
| Q64992859 | Roles of Shiga Toxins in Immunopathology. |
| Q33403359 | STEC-HUS, atypical HUS and TTP are all diseases of complement activation |
| Q39846215 | STEC:O111-HUS complicated by acute encephalopathy in a young girl was successfully treated with a set of hemodiafiltration, steroid pulse, and soluble thrombomodulin under plasma exchange |
| Q64270699 | Sepsis-associated disseminated intravascular coagulation and its differential diagnoses |
| Q39392213 | Shiga toxin 1 causes direct renal injury in rats |
| Q33400603 | Shiga toxin 1 induces on lipopolysaccharide-treated astrocytes the release of tumor necrosis factor-alpha that alter brain-like endothelium integrity |
| Q24538771 | Shiga toxin 2 and lipopolysaccharide induce human microvascular endothelial cells to release chemokines and factors that stimulate platelet function |
| Q47321222 | Shiga toxin triggers endothelial and podocyte injury: the role of complement activation |
| Q33382197 | Shiga toxin-2 results in renal tubular injury but not thrombotic microangiopathy in heterozygous factor H-deficient mice. |
| Q33389321 | Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction |
| Q42438485 | Shigatoxin-1 binding and receptor expression in human kidneys do not change with age. |
| Q33402784 | Shigatoxin-associated hemolytic uremic syndrome: current molecular mechanisms and future therapies |
| Q41837398 | Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling |
| Q33439653 | Shigella sonnei and hemolytic uremic syndrome: A case report and literature review |
| Q46275241 | Soluble CD40 Ligand and Oxidative Response Are Reciprocally Stimulated during Shiga Toxin-Associated Hemolytic Uremic Syndrome. |
| Q24543850 | Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome |
| Q33409586 | Successful conversion to belatacept after thrombotic microangiopathy in kidney transplant patients |
| Q33434722 | Susceptibility Etching on MRI in Patients with Microangiopathy |
| Q33393979 | Suspicious neuroimaging pattern of thrombotic microangiopathy |
| Q33370540 | Systemic antithrombotic effects of ADAMTS13. |
| Q33392975 | Targeting von Willebrand factor and platelet glycoprotein Ib receptor |
| Q35097528 | The complement inhibitors Crry and factor H are critical for preventing autologous complement activation on renal tubular epithelial cells. |
| Q28300378 | The development of atypical hemolytic uremic syndrome depends on complement C5 |
| Q41922057 | The evolutionary divergence of Shiga toxin-producing Escherichia coli is reflected in clustered regularly interspaced short palindromic repeat (CRISPR) spacer composition |
| Q33428892 | The long-term outcomes of atypical haemolytic uraemic syndrome: a national surveillance study |
| Q33352815 | The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children |
| Q33374578 | The role of von Willebrand factor in hemorrhagic and thrombotic disorders |
| Q33344705 | Therapeutic plasma exchange and plasma infusion in thrombotic microvascular syndromes |
| Q40593336 | Thrombotic microangiopathy and human immunodeficiency virus in the era of eculizumab |
| Q46991150 | Thrombotic microangiopathy as a complication in a patient with focal segmental glomerulosclerosis |
| Q52650422 | Thrombotic microangiopathy associated with Mycoplasma pneumoniae infection. |
| Q33415320 | Thrombotic microangiopathy complicating newly diagnosed Sjögren's syndrome in a dialysis patient |
| Q33383282 | Thrombotic microangiopathy in pregnancy |
| Q33428025 | Thrombotic thrombocytopenic purpura following salvage chemotherapy with paclitaxel, ifosfamide and cisplatin in a patient with a refractory germ cell tumor: A case report and review of the literature |
| Q33377727 | Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis |
| Q33395253 | Transplant-associated thrombotic microangiopathy in pediatric patients treated with sirolimus and tacrolimus |
| Q33380757 | Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). |
| Q33371969 | Vascular lesions in nine Göttingen minipigs with thrombocytopenic purpura syndrome |
| Q52866918 | Von Willebrand factor regulates complement on endothelial cells. |
Search more.